September 2022 - anaveon

Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022

by admin | Sep 10, 2022 | Press Releases

– ANV419 is well-tolerated at high doses and demonstrates notable safety with strong pharmacodynamic effects and excellent IL-2R-beta-gamma selectivity – – A Phase II program of ANV419 has been initiated in Melanoma and multiple combination trials,...

Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022

Search here

Categories

Recent Posts

Archives

Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022

Search here

Categories

Recent Posts

We are social

Popular Tags

Archives